Novo Nordisk Resumes P-III Study of Concizumab for Patients with Hemophilia A and B

 Novo Nordisk Resumes P-III Study of Concizumab for Patients with Hemophilia A and B

Novo Nordisk Resumes P-III Study of Concizumab for Patients with Hemophilia A and B

Shots:

  • The company resumes the P-III program (explorer6, 7, and 8) of concizumab. The clinical trials are evaluating concizumab (SC) prophylaxis treatment in hemophilia A and B patients regardless of their inhibitor status
  • The trials will be resumed as soon as local procedures allow. This follows pausing of the trials in Mar’20 due to the occurrence of non-fatal thrombotic events in 3 patients enrolled in the ongoing P-III program
  • In Oct 2019, Novo Nordisk has initiated the explorer7 study to establish the safety and efficacy of concizumab (SC, qd) delivered in a pen device to reduce the number of bleeds in patients with hemophilia A or B with inhibitors towards FVIII/ FIX. In Nov 2019, the company initiated P-III explorer8 study in hemophilia A or B patients without inhibitors. The trials are to enroll ~293 patients across 32 countries

Click here ­to­ read full press release/ article | Ref: Novo Nordisk  | Image: Scrip Informa

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post